Label-free nanoplasmonic sensing of tumor-associate autoantibodies for early diagnosis of colorectal cancer |
| |
Authors: | Maria Soler M.-Carmen Estevez Roi Villar-Vazquez J. Ignacio Casal Laura M. Lechuga |
| |
Affiliation: | 1. Nanobiosensors and Bioanalytical Applications Group (NanoB2A), Catalan Institute of Nanoscience and Nanotechnology (ICN2), CSIC and The Barcelona Institute of Science and Technology, Campus UAB, Bellaterra, 08193, Barcelona, Spain;2. CIBER-BBN Networking Center on Bioengineering, Biomaterials and Nanomedicine, Spain;3. Functional Proteomics Group, Centro de Investigaciones Biológicas (CIB-CSIC), 28040, Madrid, Spain |
| |
Abstract: | Colorectal cancer is treatable and curable when detected at early stages. However there is a lack of less invasive and more specific screening and diagnosis methods which would facilitate its prompt identification. Blood circulating autoantibodies which are immediately produced by the immune system at tumor appearance have become valuable biomarkers for preclinical diagnosis of cancer. In this work, we present the rapid and label-free detection of colorectal cancer autoantibodies directly in blood serum or plasma using a recently developed nanoplasmonic biosensor. Our nanoplasmonic device offers sensitive and real-time quantification of autoantibodies with excellent selectivity and reproducibility, achieving limits of detection around 1 nM (150–160 ng mL−1). A preliminary evaluation of clinical samples of colorectal cancer patients has shown good correlation with ELISA. These results demonstrate the reliability of the nanobiosensor strategy and pave the way towards the achievement of a sensitive diagnostic tool for early detection of colorectal cancer. |
| |
Keywords: | Nanoplasmonic biosensor Plasma Serum Colorectal cancer Autoantibodies Clinical diagnosis |
本文献已被 ScienceDirect 等数据库收录! |
|